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ABSTRACT
Hypertrophic scar (HS) and keloid (KL) are two forms of an abnormal cutaneous
scarring process, mainly characterized by excessive extracellular matrix deposi-
tion and ﬁbroblast proliferation. Despite the increased understanding of the mo-
lecular and cellular events leading to HS and KL, the pathogenesis of these
lesions remains poorly understood. A pivotal role in the formation of abnormal
scars has been ascribed to transforming growth factor-b, whose activity appears
to be mediated through a link with pathways acting via cyclooxygenases (COX-1
and COX-2). To date, there is no report on the in vivo expression of COX-1 and
COX-2 in human HS and KL tissues. Therefore, using immunohistochemistry
andWestern blot analysis, we investigated 36 cases of KL, 32 cases of HS, and 25
cases of normal skin in order to deﬁne the localization and distribution of COX-1
and COX-2 in the tissues of these scar lesions and the overlying epidermis. The
results mainly show the following: (a) a signiﬁcant overexpression of COX-1 in
HS tissues and the overlying epidermis as compared with normal skin and KL
tissues and (b) a signiﬁcant overexpression of COX-2 in KL tissue and the over-
lying epidermis in contrast to normal skin and HS tissues. Our data support the
hypothesis that both COXs are involved in the pathogenesis of scar lesions in
different ways and, particularly, COX-1 in the formation of HS and COX-2 in the
formation of KL. In addition, the overexpression of COX-1 and COX-2 in
the epidermis overlying HS and KL tissues, respectively, underlines the impor-
tance of epithelial–mesenchymal interactions in the pathogenesis of scar lesions.
Hypertrophic scar (HS) and keloid (KL) represent two
forms of an abnormal wound-healing process character-
ized by local ﬁbroblast proliferation and excessive collagen
production in response to a cutaneous injury. However,
HS and KL show signiﬁcant differences in their clinical
features, histology, and pathogenesis. Clinically, by deﬁni-
tion, KL exceeds the wound margin, often with claw-like
extensions resembling ‘‘the pincers of a crab’’ involving the
normal adjacent skin, whereas an HS remains conﬁned to
the site of the original injury.1–3 The lesion appears as a
ﬁrm, mildly tender, nodule or plaque more irregular in KL
than HS, and is often pruritic and painful. Usually, HS
shows signs of regression after a few months and may
resolve spontaneously.
In contrast, KL tends to grow to a certain size. Subse-
quently, KL stops growing and may display some regres-
sion, usually partial and slow, but in rare case it may
relentlessly progress.
To date, epidemiologic data onHS andKL are insufﬁcient
but suggest a greater susceptibility to KL formation in
darker-pigmented races, Hispanics and Asians, as distinct
from Caucasians and albinos, who are much less affected.1,2
KLs may occur at any age but most reported cases have oc-
curred in individuals between 10 and 30 years of age.1
From a histological viewpoint, unequivocal criteria for
a deﬁnite distinction between KL and HS have not yet
been established. Histologically, KL shows thickened,
hyalinized, brightly eosinophilic-staining collagen bun-
dles, classically described as ‘‘keloidal collagen,’’1,3 with
an irregular orientation. This contrasts with an HS, where
collagen bundles are oriented parallel to the epidermis. In
addition, KL displays abundant mucin between the colla-
gen bundles and tends to be less cellular than HS.
Nevertheless, the presence of ‘‘keloidal collagen’’ is
rarely reported in HS and may be lacking in KL.1,2 To
clarify this differential diagnosis, Lee et al.3 proposed
other histological features characteristic for KL such as
the absence of prominent vertically oriented blood vessels,
the presence of a tongue-like advancing edge underneath a
normal-appearing epidermis and papillary dermis, hori-
zontal ﬁbrous bands in the upper reticular dermis, and a
prominent fascia-like band.
a-smooth muscle actin expression failed as a differenti-
ating marker because it is present in both KL and HS.3
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In an attempt to clarify the pathogenesis of HS and KL,
several hypotheses and numerous etiological factors have
been proposed, but to date the mechanism of formation of
abnormal wound healing appears to be rather complex
and multifactorial, and its complete understanding has not
been achieved as yet.
Some etiological factors proposed are as follows:
trauma or inﬂammation of the skin, infection, aberrant
metabolism of the melanocyte-stimulating hormone, phys-
iologic hyperactivity of the pituitary gland, genetic and fa-
milial disorders, nutritional deﬁciencies in Fas, and p53
gene mutation.1–4
The spontaneous onset of KLs reported occasionally by
patients probably represents a trauma that was forgotten
or unnoticed by the patient.2
The existence of at least some form of genetic suscepti-
bility has been suggested by the description of families
with multiple affected members from KLs5 but to date no
genes favoring the formation of KLs have been identiﬁed.
In addition, several studies have recently indicated that
several factors such as interleukin-1b (IL-1b),6 tumor ne-
crosis factor-a (TNF-a), numerous cytokines,7 and growth
factors such as vascular endothelial growth factor (VEGF),
platelet-derived growth factor (PDGF), connective tissue
growth factor (CTGF), and transforming growth factor-b
(TGF-b) may be involved in the pathogenesis of KL.8,9
In particular, TGF-b stimulates matrix proteins such as
collagen, inhibits protease production, and enhances mi-
togenesis.10 Recent in vitro studies have hypothesized the
possible pivotal role of TGF-b1 overexpression in KL ﬁ-
broblasts in the pathogenesis of KL.2–10
Results from cell culture experiments support the hy-
pothesis that TGF-b1 has a function as an upstream regu-
lator of the cyclooxygenase (COX) pathway, and also that
the growth promotion by TGF-b is mediated through a
link with the COX pathway.2,11
COXs catalyze the conversion of arachidonic acid,
which is derived from membrane phospholipids by
phospholipase, into prostaglandins.12 There are two main
COX isoforms, COX-1 and COX-2, which share the same
substrates, generate the same products, and catalyze the
same reactions using identical mechanisms. Nevertheless,
COX-2 is signiﬁcantly more efﬁcient than COX-1 with re-
spect to the enzymatic activity.12
COXs appear to be involved in tumorigenesis of numer-
ous neoplasia such as carcinoma of the breast, prostate,
skin, colorectum, lung, bladder, stomach, and Kaposi’s
sarcoma by several pathogenetic mechanisms, including
neoangiogenesis, ﬁbrosis, proliferative activity, regulation
of expression of integrins, matrix metalloproteinases
(MMPs), p53, and bcl-2.12–15
In a previous study,15 we reported a signiﬁcant overex-
pression of COX-1 and COX-2 not only in spindle cells of
classic and epidemic Kaposi’s sarcoma tissues but also in
keratinocytes of epidermis overlying KS compared with
control skin tissues.
In fact, a growing number of signiﬁcant studies in the
literature2,8,9,16 indicate interactions between the epider-
mis and dermal tissue, which play an important role in the
regulation of homeostasis, growth, and differentiation of
epithelial and mesenchymal tissue. Besides COXs, keratin-
ocytes synthesize and release a broad variety of factors,
cytokines, and chemokines that modulate the activity of
other epithelial cells as well as of dermal ﬁbroblasts, endo-
thelial cells (ECs), and macrophages in a paracrine and
autocrine manner, as reported by various studies.16–18
These data strongly suggest that the overlying epidermis
is not just a protective barrier, but that epidermal cells in-
teract closely with the underlying dermis.
In addition, COXs also seem to be implicated in the
pathogenesis of abnormal wound healing as also shown by
the reduction of formation of KL and scar in patients us-
ing a nonsteroidal anti-inﬂammatory drug and a COX-2
inhibitor.2,19
Therefore, the aim of this study was to assess in vivo the
distribution and localization of COX-1 and COX-2 by the
immunohistochemical method in KL and HS tissues and
also in the epidermis overlying these lesions.
MATERIALS ANDMETHODS
Our research complies with the ethical rules for human ex-
perimentation that are stated in the 1975 Declaration of
Helsinki, and was approved by the appropriate Institu-
tional Review Boards.
Sixty-eight untreated scar lesions were used for this in-
vestigation: 36 cases of KL and 32 cases of HSs. Patients
ranged in age from 5 to 58 years (mean age of 42 years).
KLs had been present for at least 6 months and were
located in the ear lobes and face (16 case), shoulders (8),
arms (5), chest wall (3), neck (2), and abdominal wall (2).
HSs were located in the head and neck region (12 cases),
chest wall (8), shoulders (7), knees (3), and abdominal wall
(2). Twenty-ﬁve cases of normal skin were also used as
control tissue.
All biopsy tissues were formalin ﬁxed and embedded in
parafﬁn using a routine histological procedure; 5-mm-thick
sections were cut from each specimen. Afterwards, slides
were deparafﬁnized and then rehydrated in graded alco-
hols according to the standard protocol.
Immunostaining was performed as reported previously
in detail.15 The following primary antibodies were used for
immunohistochemistry: monoclonal mouse antibodies for
CD34, CD45 (LCA), CD68 (Immunomarkers-Diapath,
Martinengo, Italy), monoclonal mouse antibodies for
COX-1 and COX-2 (Novocastra, Newcastle, UK), and b-
actin (Santa Cruz Biotechnology, Santa Cruz, CA). The
sections were immunostained with a streptavidin–biotin
system using an automated slide stainer (Benchmark,
Ventana Medical System, Tucson, AZ). The omission, re-
placement, and inversion of the primary antibody were
carried out as negative controls.
The double-labeling technique was performed using the
Ultra-View Universal Alkaline Phosphatase Detection Kit
(Ventana-Diapath, Tucson, AZ, USA) using Fast red and
DAB as chromogens according to the procedure indicated
by Ventana. For each section, the staining pattern of
COX-1 and COX-2 was scored for the percentage of pos-
itive cells (A5 < 10% of positive cells; B5from 11 to
30%; C5 > 31% of cells).
A semi-quantitative scale (15weak intensity;
115moderate intensity; 1115intensive staining) was
used only for the assessment of the intensity of staining
pattern by COX-1 in the epidermis.
A comparison between different percentages of positive
cells was not possible because COX-1 is always expressed
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in almost all epithelial cells of both control normal skin
and the epidermis overlying scar lesions.
Three observers (R.R., R.L., M.E.P.) separately esti-
mated the staining pattern and percentages of positive cells
of each section by counting the number of COXs-positive
cells per viewing ﬁeld at a magniﬁcation of 400.
The level of concordance, expressed as the percentage of
agreement between observers, was 91% (133 of 146 spec-
imens). All specimens with a discordant score were reeval-
uated by investigators using a multiheaded microscope
and a consensus was reached after collegial revision.
The level of concordance was 100% as regards the diag-
nosis of KL and HS.
The protein extraction was performed by modifying the
previously described method.20,21 In brief, four tissue sec-
tions obtained from nine cases of HS and eight cases of KL
were deparafﬁnized with xylene three times for 10 minutes
and placed in 100% ethanol for washing three times for 10
minutes. After air drying, protein from deparafﬁnized tis-
sue was solubilized in 1% sodium dodecyl sulfate (SDS)
and 100mM NaHCO3, incubated at 65 1C overnight, and
sonicated for 2 minutes. Proteins were precipitated with
10% TCA before solubilization in 60 mL of a cross-linking
reversal solution (tris-HCL 0.250M pH 8.8; glycerol 10%,
w/v; SDS 2%, w/v; 2-mercaptoethanol 0.5M), from form-
aldehyde cross-link reverse, and incubated for 25 minutes
at 99 1C.21 Ten microliters of samples were run in SDS
10% polyacrylamide gels (bis/mono 1 : 37.5) on a Mini-
Protean II apparatus (BioRad, Hercules, CA) according to
the Leammli electrophoresis method.22 Western blot anal-
ysis and peroxidase activity were performed according to
the manufacturer’s instructions (Amersham Bioscience,
Buckinghamshire, UK) using an ECL-AdvancedTM
chemiluminescence kit (GEHealthcare, Buckinghamshire,
UK) with monoclonal antibodies anti-COX-1 (1/2000),
and anti-COX-2 (1/600). Protein loading was controlled
by anti-b-actin. Ten microliters of same samples were used
to determine the amounts of protein (100–10 kDa) by Coo-
massie blue G-250 staining electrophoresis gel, compared
with a total of 2 mg of a broad-range protein standard
(BioRad) as described by Becker et al.23 The amount of
protein of each sample ranged between 2 and 5mg for the
electrophoresis lane. Densitometric analysis of tif scan im-
ages, both Western blot and stained slides, obtained using
Arcus II Agfa, was performed using TotalLab 1D (Non-
Linear Dynamics, Newcastle, UK).
Descriptive statistics were used to summarize the mor-
phologic evaluation of immunohistochemical data. Com-
parisons between the groups were made by the Fisher
exact test and Pearson chi-square when appropriate;
p value < 0.05 was considered statistically signiﬁcant.
RESULTS
As described by us previously,15 COX-1 positivities in nor-
mal skin appeared to be uniformly distributed in all epithe-
lial layers of the epidermis, showing faint or moderate
staining; in contrast, COX-2 was absent or focally expressed
in epithelial cells mostly of the upper layers (Table 1).
In the dermis, a variable percentage of ECs and ﬁbro-
blasts showed COX-1 staining, whereas COX-2 positivities
were sometimes detected in macrophages, lymphocytes,
and ﬁbroblasts (Table 1).
With regard to the cases of HS, immunostaining for
COX-1 revealed intensive and diffuse positivities in epithe-
lial cells of the epidermis overlying a scar lesion as well
as in ﬁbroblasts and ECs, whereas COX-2 expression
appeared to be less intensive and diffuse as reported in
Table 2.
The comparison between normal skin and tissues in-
volved in HS revealed that more intensive and diffuse
staining for COX-1 was detected in a scar lesion as com-
pared with the normal epidermis and dermal tissue (differ-
ences statistically signiﬁcant for both: p < 0.001).
With regard to COX-2, the immunohistochemical re-
sults showed less intensive and diffuse positivities in HS
tissues as compared with the staining pattern displayed by
COX-1 (Table 2).
The comparison between normal skin and HS indicated
a minimal expression of COX-2 in both the epidermis and
Table 1. COX-1 and COX-2 in normal skin
COX-1 COX-2
Epidermis Dermal cellsn Epidermis Dermal cellsn
Value N % Value N % N % N %
1w 20 80 0z 9 36 17 68 11 44
11 5 20 A 16 64 8 32 13 52
111 0 0 B 0 0 0 0 1 4
 – – C 0 0 0 0 0 0
nFibroblasts, endothelial cells, macrophages, lymphocytes.
wSemi-quantitative scale from 1(weak staining ), 11 (moder-
ate staining), 111 (intensive staining).
zScore for percentage of positive cells from 0 (no positive cells)
to A (1–10% of positive cells), B (11–30% of positive cells), C
( > 31% of positive cells).
COX, cyclooxygenase.
Table 2. COX-1 and COX-2 expression in hypertrophic scar
(HS) tissues and overlying epidermis
COX-1 COX-2
Epidermis Dermal cellsn Epidermis Dermal cellsn
Value N % Value N % N % N %
1w 0 0 0z 0 0.0 21 65.6 15 46.9
11 17 53.1 A 3 9.4 10 31.3 14 43.7
111 15 46.9 B 12 37.5 1 3.1 3 9.4
 – – C 17 53.1 0 0.0 0 0.0
nFibroblasts, endothelial cells, macrophages, lymphocytes.
wSemi-quantitative scale from 1 (weak staining ), 11 (moder-
ate staining), 111 (intensive staining).
zScore for percentage of positive cells from 0 (no positive cells)
to A (1–10% of positive cells), B (11–30% of positive cells), C
(> 31% of positive cells).
COX, cyclooxygenase.
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Figure 1. Hypertrophic scar (HS). (A) Morphological
picture of HS: nodular fibroblastic proliferation within
the dermis (hematoxylin–eosin, 100). (B) Higher mag-
nification of the previous picture: the lesion is com-
posed of fibroblasts with a variable collagenous stroma
(hematoxylin–eosin, 200). (C) Intensive staining for
cyclooxygenase-1 (COX-1) in both the epidermis (ar-
row) and dermal spindle cells (400). (D) Intensive
staining for COX-1 in dermal spindle cells (400). (E)
Lack of COX-2 staining in both the epidermis and der-
mal tissue (100). (F) Few and faint COX-2 positivities
in dermal spindle cells and lymphocytes (200).
100 µm
A B C
FED 100 µm100 µm100 µm
100 µm100 µm
Figure 2. Keloid (KL). (A) Morphological appearance
of KL also showing broad bundles (keloidal collagen) of
eosinophilic hyalinized collagen (hematoxylin–eosin,
100). (B) Keloidal collagen at a higher magnification
(hematoxylin–eosin,200). (C) Intensive cyclooxygen-
ase-2 (COX-2) staining in the epidermis (400). (D) In-
tensive COX-2 staining identifiable in dermal
fibroblasts (400). (E) Lack of COX-1 staining in both
the epidermis and dermal tissue (200). (F) Few and
faint positivities for COX-1 in dermal cells (200).
20 µm A
C
B
D20 µm
20 µm
20 µm
Figure 3. Double labeling technique (chromogens:
AEC-red, DAB-brown) in keloid (KL) lesions. (A) Coex-
pression of CD68 (red) and cyclooxygenase-2 (COX-2;
brown) occurs in two dermal macrophages, whereas
the epidermis only shows an intense expression of
COX-2 (1000). (B) Coexpression of CD68 (red) and
COX-2 (brown) occurs in some macrophages,
whereas endothelial cells (ECs) show staining only for
COX-2 (1000). (C) Coexpression of LCA (red) and
COX-2 (brown) in lymphocytes (1000). (I) Coexpres-
sion of CD34 (red) and COX-2 (brown) in ECs of a der-
mal vessel (630).
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the dermal cells (Figure 1). The differences were not statis-
tically signiﬁcant (normal epidermis/epidermis overlying
HS tissues: p50.12; dermal cells of normal skin/HS tissues:
p50.066).
The staining patterns of COX-1 and COX-2 in KLs and
the overlying epidermis are summarized in Table 3.
The comparison between normal skin and KL tissues
did not show remarkable variations in the expression of
COX-1 in the epidermis (p50.087), whereas a weak sig-
niﬁcant difference (p50.01042) was found between dermal
cells of normal skin and KL tissues.
In contrast, COX-2 expression (Figure 2) was more sig-
niﬁcantly increased in the epidermis and dermal cells (ﬁ-
broblasts and ECs) of KL tissues in comparison with
normal epidermis and dermis (normal epidermis/epider-
mis overlying KL tissues: p < 0.0001; demal cells of nor-
mal skin/KL tissues: p < 0.0001).
Particularly in KL tissues, ECs and ﬁbroblasts often
displayed moderate/strong positivities for COX-2 (Figure
2), as well as macrophages and lymphocytes, often distrib-
uted around dermal vessels, whereas focal or weak staining
was observed for both COXs in the dermal inﬂammatory
cells of HS tissues.
Indeed, the double-staining technique revealed in KL
tissues coexpression of COX-2 and CD34, CD68, and
CD45 in ECs, macrophages, and lymphocytes, respec-
tively (Figure 3).
The expression of COX-1 and COX-2 in scar lesions as
well as in the overlying epidermis showed remarkable and
signiﬁcant differences between HS and KL, as reported in
Figures 4 and 5.
COX-1 was signiﬁcantly overexpressed in HS and the
overlying epidermis in comparison with KL tissues. In
contrast, COX-2 was signiﬁcantly overexpressed in KL
tissue and the overlying epidermis as compared with HS
tissues.
The expression of COX-1 and COX-2 molecules in HS
and KL lesions was analyzed by aWestern blot assay (Fig-
ure 6B). An expected molecular weight band of 69 kDa,
detected by the anti-COX-2 antibody in the entire KL
sample group and in four out of nine in the HS sample
group, is shown (Figure 4). Instead, the anti-COX-1 anti-
body weakly shows a molecule of 68 kDa present in both
groups of samples. The different expression of two mole-
cules was highlighted by densitometric analysis. In fact,
the analysis of the means of single sample volume density
showed a COX-1 prevalence in the ﬁrst group (HS) and
COX-2 in the KL group (Figure 6A left). The measure of a
speciﬁc b-actin band (43 kDa) present on the same samples
did not show differences between the HS and the KL
group. Densitometric Western blot data were normalized
Table 3. COX-1 and COX-2 expression in keloid (KL) tissues
and overlying epidermis
COX-1 COX-2
Epidermis Dermal cellsn Epidermis Dermal cellsn
Value N % Value N % N % N %
1w 24 66.7 0z 8 22.2 0 0.0 0 0.0
11 11 30.5 A 23 63.9 2 5.6 3 8.3
111 1 2.8 B 5 13.9 22 61.1 16 44.5
 – – C 0 0.0 12 33.3 17 47.2
nFibroblasts, endothelial cells, macrophages, lymphocytes.
wSemi-quantitative scale from 1 (weak staining ), 11 (moder-
ate staining), 111 (intensive staining).
zScore for percentage of positive cells from 0 (no positive cells)
to A (1–10% of positive cells), B (11–30% of positive cells), C
( > 31% of positive cells).
COX, cyclooxygenase.
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KL 66.7 30.5 2.8 0 8.3 44.5 47.2
+ ++ +++ 0 A B C
COX-1
Figure 4. Cyclooxygenase-1 (COX-1) expression in hypertro-
phic scar (HS) and keloid (KL) tissues by immunohistochemis-
try. The staining pattern of COX-1 and COX-2 was scored for
percentage of positive cells (A5 < 10% of positive cells;
B5from 11 to 30%; C5 > 31% of cells). A semi-quantitative
scale (15weak intensity; 115moderate intensity; 1115in-
tensive staining) was used only for the assessment of the in-
tensity of the staining pattern by COX-1 in the epidermis.
0
10
20
30
40
50
60
70
%
HS
KL
HS 65.6 31.3 3.1 0 46.9 43.7 9.4 0
KL 0 5.6 61.1 33.3 0 8.3 44.5 47.2
O A B C 0 A B C
COX-2
Figure 5. Cyclooxygenase-2 (COX-2) expression in hypertro-
phic scar (HS) and keloid (KL) tissues by immunohistochemis-
try. The staining pattern of COX-1 and COX-2 was scored for
percentage of positive cells (A5 < 10% of positive cells; B 5
from 11 to 30%; C5 > 31% of cells). A semi-quantitative scale
(15weak intensity; 115moderate intensity; 1115intensive
staining) was used only for the assessment of the intensity of
the staining pattern by COX-1 in the epidermis.
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for a loaded amount of proteins. The COX-1 and COX-2
values of each sample, represented by the dispersion graph
in Figure 6A, showed a different scattering of groups in
two speciﬁc areas. Only one HS sample was present in the
KL group area.
DISCUSSION
The results lead to the following main conclusions:
1. COX-1 is signiﬁcantly overexpressed in HS tissues and
in the overlying epidermis in comparison with normal
skin.
2. COX-2 expression in HS tissues and in the epidermis
overlying a scar lesion displays no signiﬁcant differ-
ences as compared with normal skin.
3. KL tissues are characterized by a remarkable overex-
pression of COX-2 in a dermis scar lesion and in the
overlying epidermis in comparison with HS tissues as
well as with normal skin.
Despite the expected difﬁculties of the procedure used
for protein extraction (from ﬁxed tissue sections) and the
limitations of the Western blot, we may state that the re-
sults obtained appear to be consistent with the immuno-
histochemistry observations.
Our results might indicate a role for COX-1 in the
pathogenesis of HS, whereas COX-2 only appears to be
implicated in the pathogenetic mechanisms involved in KL
scarring.
Cultured keloidal ﬁbroblasts have been found to have
an increased production of collagen and MMPs, lower
rates of apoptosis and down-regulation of apoptosis-re-
lated genes, and a high proliferation rate as compared with
normal dermal ﬁbroblasts.2,6–8,10 Several studies have in-
dicated that certain cytokines frequently produced by
these ﬁbroblasts, acting as autocrine or paracrine factors,
participate in abnormal wound scarring6–8,24–26 such as
some transcription factors, TNF-a, interleukins, VEGF,
PDGF, CTGF, insulin-like growth factor-1 (IGF-1) and,
chieﬂy, TGF-b.
Indeed, TGF-b plays a major role in metabolic path-
ways and gene domains associated with scar and KL for-
mation. Particularly, TGF-b induces prostaglandin
production in cultured ﬁbroblasts by overexpression of
COX-1, as demonstrated by some investigators.27,28
Nevertheless, up-regulation of TGF-b expression may
be considered necessary but not sufﬁcient for excessive
scarring because HS and KL formation is a multistep pro-
cess that requires complex interactions of multiple fac-
tors.2,25
In addition, other factors might be implicated in the
pathogenesis of KL to explain the overexpression of COX-
2 in KL, because TGF-b mainly induces COX-1 expres-
sion. Among these, an important factor involved in the
wound-healing process is TNF-a, which induces nuclear
factor-kb (NF-kb) activation in ﬁbroblasts; NF-kb is
a transcription factor involved in signaling transduc-
tion pathways regulating proliferation, angiogenesis,
and apoptosis.26,28,29
NF-kb and its target genes, especially the antiapoptotic
genes, are up-regulated in KL ﬁbroblasts.26,29 Recent ﬁnd-
ings26 also show that activation of NF-kb is responsible
for TNF-a–induced COX-2 overexpression in KL ﬁbro-
blasts.
In addition, several experimental and clinical investiga-
tions2,19,30 have shown that down-regulation of COX-2
may reduce scar and KL formation and also that various
COX-2 inhibitors have shown some beneﬁcial inﬂuence on
KL management.
Moreover, it has been shown2,3,8,31 that occlusion of mi-
crovessels and decreased vascular density frequently occur
Figure 6. Western blot analysis of
hypertrophic scar (HS) (dark gray)
and keloid (KL) (light gray) cell ex-
tracts. A left densitometric analysis
of Western blot samples with
anti-cyclooxygenase-1 (COX-1), anti-
COX-2, and anti-b-actin antibodies.
The bars indicate the mean of sam-
ple groups HS and KL with relative
SD normalized for loaded proteins.
(A) Right dispersion graph of single
sample density for anti-COX-1 in the
x-axis and anti-COX-2 in the y-axis.
(B) Western blot analysis of HS and
KS cell extracts using polyclonal anti-
COX-1, polyclonal anti-COX-2, and
anti-b-actin antibodies. Lanes from 1
to 9 samples are of the HS group
while lanes from 10 to 17 are those
of the KL group.
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in KL compared with HS and normal scars. These ﬁndings
suggest that hypoxia in KL tissues8 may play an important
role.
The signiﬁcant differences in relation to the expression
of COX-1 and COX-2 in abnormal wound tissues suggest
different molecular mechanisms involved in the pathogen-
esis of HS and KL. In contrast to certain authors,2,31 who
have stated that a precise distinction between HS and KL
is not always possible and that the two lesions represent a
continuous spectrum, HS and KL display remarkable clin-
ical, morphological, and molecular differences.32,33
Indeed, KL represents abnormal wound healing show-
ing characteristics similar to tumors such as a tendency to
grow beyond the site of original injury and to recur,
whereas HS remains within the boundaries of the original
lesion, does not recur, and may spontaneously regress.1,3,31
In addition, HS is histologically characterized by dermal
nodular proliferation of ﬁbroblasts and myoﬁbroblasts,
oriented parallel to the epidermis, whereas KL tissues
show abundant extracellular matrix, eosinophilic acellular
bands of collagen, thickened hyalinized collagen bundles
with an irregular orientation, and relatively few ﬁbro-
blasts.1,3,31
Also, molecular characteristics display some remark-
able differences because KL ﬁbroblasts show higher up-
regulation of VEGF, higher volume density of elastin,
overexpression of protease-activated receptors and muta-
tion of p53, a lower level of connexin 43, and a higher re-
sistance to FAS-mediated apoptosis as compared with HS
ﬁbroblasts.34–36
Our ﬁndings conﬁrm these remarkable molecular differ-
ences between the two lesions. The behavior of normal
skin and epidermis overlying scar lesions should also
be emphasized as regards the expression of COX-1 and
COX-2.
As reported by us previously,15 immunohistochemistry
reveals that COX-1 is generally present throughout all lay-
ers of the epidermis of normal skin, whereas COX-2 may
be absent or expressed in more differentiated suprabasal
keratinocytes.
In the epidermis overlying scar lesions, COXs expres-
sion parallels the staining pattern of COX-1 and COX-2 in
scar lesions: COX-1 is mainly overexpressed in both HS
dermal tissues and the overlying epidermis, whereas COX-
2 is overexpressed in both KL tissues and the overlying
epidermis. These ﬁndings strongly underline the involve-
ment of keratinocytes in the multistep process related to
HS and KL formation. Indeed, the epidermis overlying
dermal ﬁbrotic lesions is no longer considered solely as a
protective barrier, because epidermal cells contribute to
normal and abnormal wound-healing processes by regu-
lating dermal matrix accumulation and degradation of
collagen, proliferation, and apoptosis of ﬁbroblasts as well
as angiogenesis through epithelial–mesenchymal signaling
in a paracrine fashion.8,9,16–18,36 It has been clearly shown
that keratinocytes secrete several proteins and cytokines
such as TGF-b, CTGF, EGF, FGF-2, IGF-1, VEGF,
PLGF, KGF, and IL-1, which have an important para-
crine effect on underlying ﬁbroblasts.8,9,16–18,37,38
Our results reinforce the importance of epithelial/
mesenchymal interaction in stimulating an abnormal
wound-healing multistep process and the remarkable role
of keratinocytes in the behavior of dermal ﬁbroblasts.
Furthermore, COX-2 has also been detected in macro-
phages and lymphocytes of KL tissues other than in ﬁbro-
blasts and ECs as shown by the double immunostaining
technique. In a previous study,15 we also found similar re-
sults revealing COX-2 expression in macrophages and
lymphocytes, in contrast to COX-1, which was mainly de-
tected only in ﬁbroblasts and ECs. Experimental stud-
ies25,39 and morphological observations2,26,31 suggest that
during scar formation, inﬂammation plays a remarkable
role that results in an increases of macrophages, leuko-
cytes, and collagen deposition. Indeed, inﬁltrating inﬂam-
matory cells may be detected in normal and abnormal
scarring tissues2,3,29,40 and these cells may also contain
several cytokines.29,40 These data and our ﬁndings suggest
that inﬂammatory cells may contribute to the development
of KL also by COX-2 expression. Moreover, COX-2’s re-
markable positivities in KL tissues, in spite of intensive
staining of COX-1 in HS tissues, might be used as a further
criterion for a deﬁnite histological distinction between KL
and HS.
There is little understanding of the molecular and cellu-
lar mechanisms leading to the formation of KL and HS at
present, and no adequate animal model is available be-
cause these scar lesions only occur in humans.
On the other hand, these lesions are still extremely chal-
lenging, particularly in their variable response to treat-
ment. Nevertheless, our in vivo data support the
hypothesis that COX-1 and COX-2 may be implicated in
different ways in the molecular mechanisms involved in
HS and KL formation, respectively.
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